drugset
Drugs / FTC/TDF
last change Mar 2019 re-read 2 minutes ago

FTC/TDF

also known as emtricitabine with tenofovir disoproxil fumarate

Small molecule

Developed for
HIV infectious disease
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

today NCT02121795 · Ph 3
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02121795 May 2014 → Aug 2015 HIV infectious disease Gilead Sciences Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2016-10-24 Gilead Sciences Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as FTC/TDF ClinicalTrials.gov intervention name — accepted as the source's own label NCT02121795 ↗
Known as emtricitabine with tenofovir disoproxil fumarate “Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.” PMID 27036991 ↗ Mar 2016
Modality Small molecule “Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.” PMID 27036991 ↗ Mar 2016
Route Oral “200/300 mg FDC tablets administered orally once daily” NCT02121795 ↗